Nuvectis Pharma, Inc. NVCT shares are trending on Monday. NVCT shares surged 19.61% during Monday’s regular trading session ...

Changes in PD-L1 and tumor mutational burden between paired samples and relationship to immune checkpoint inhibitor outcomes in non-small cell lung cancer. This is an ASCO Meeting Abstract from the ...

A recent article posted to the medRxiv* preprint server discussed the role of complement factor H-related protein 5 (CFHR5) in venous thromboembolism (VTE) patients and hospitalized coronavirus ...

Although plasma factor H-related protein 5 (FHR5) levels alone were not a significant predictor of ESKD, glomerular FHR5 deposition strongly predicted progression to ESKD.

The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor ...

Shanghai Meiyue Biotech Development Co. Ltd. has synthesized spiro compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), ...

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...

Novartis AG has identified spirocyclic piperidinyl derivatives acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration (AMD), ...